» Articles » PMID: 10446917

Use of a Liver-specific Promoter Reduces Immune Response to the Transgene in Adenoviral Vectors

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 1999 Aug 14
PMID 10446917
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies using adenoviral (Ad) vectors expressing human alpha1-antitrypsin (hAAT) under the control of ubiquitous promoters (RSV, mPGK) elicited the production of antibodies to hAAT in some mouse strains (C3H/HeJ and BALB/c) but not in others (C57BL/6J). In contrast, when a helper-dependent Ad vector (AdSTK109) with all viral coding sequences deleted and expressing hAAT from human genomic DNA with the endogenous promoter was used, C3H/HeJ mice failed to develop antibodies and demonstrated long-term expression. These results suggested that promoter choice and/or properties of the vector itself might influence the host immune response to the transgene product. Direct comparison of first-generation vectors expressing the hAAT cDNA from a ubiquitous mouse PGK promoter rather than from a liver-specific mouse albumin promoter demonstrated that an antibody response to hAAT occurred with the mPGK promoter but not with the albumin promoter in C3H/HeJ mice. As expected, neither vector elicits an antibody response in C57BL/6J mice. Coinjection of the two first-generation vectors containing the mPGK and albumin promoter in C3H/HeJ mice induced an antibody response with resulting loss of detectable hAAT from the sera of the injected mice in 3-4 weeks. From these data, we conclude that under certain conditions, the choice of promoter with its associated liver-specific expression can modulate the host immune response to the transgene independent of viral backbone.

Citing Articles

Adenoviral Vectors for Gene Therapy of Hereditary Diseases.

Muravyeva A, Smirnikhina S Biology (Basel). 2025; 13(12.

PMID: 39765719 PMC: 11673936. DOI: 10.3390/biology13121052.


Strategies for Modifying Adenoviral Vectors for Gene Therapy.

Muravyeva A, Smirnikhina S Int J Mol Sci. 2024; 25(22).

PMID: 39596526 PMC: 11595218. DOI: 10.3390/ijms252212461.


Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases.

Lin C, Greenblatt M, Gao G, Shim J Hum Gene Ther. 2024; 35(9-10):317-328.

PMID: 38534217 PMC: 11302315. DOI: 10.1089/hum.2024.022.


Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels.

Trevisan B, Rodriguez M, Medder H, Lankford S, Combs R, Owen J Front Immunol. 2022; 13:1070476.

PMID: 36532079 PMC: 9755880. DOI: 10.3389/fimmu.2022.1070476.


Evading the AAV Immune Response in Mucopolysaccharidoses.

Piechnik M, Sawamoto K, Ohnishi H, Kawamoto N, Ago Y, Tomatsu S Int J Mol Sci. 2020; 21(10).

PMID: 32414007 PMC: 7279460. DOI: 10.3390/ijms21103433.